Impact of Ki67 and progesterone receptor on PFS with cyclin-dependent kinase 4/6 inhibitors in HER2-negative advanced breast cancer: A real world mono-institutional experience

Introduction: Current guidelines recommend the use of hormone therapy plus CDK 4/6 inhibitors (CDK4/6i) as initial treatments in patients (pts) with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer (ABC). The subgroup analyses of phase III studies of CDK4/6i did not identify any predictive marker that could help the clinicians to address the therapeutic choice.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: POSTERS A: Advanced Disease Source Type: research

Related Links:

Combining  abemaciclib with hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, interim analysis of a phase III study has suggested.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
(European Society for Medical Oncology) Lugano, Switzerland, 20 September 2020 - Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study at ESMO 2020.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Breast-conserving surgery (BCS) and mastectomy for early breast cancer have equivalent survival rates, with a local recurrence rate of 14.3% after 20 years of follow-up in a study. Adequate margin status after BCS is an important determinant of local recurrence. The definition of adequate surgical margins is controversial. The National Surgical Adjuvant Breast and Bowel Project B-06 trial was the only trial that defined no ink on margin as an adequate margin. Subsequent studies on margin status after BCS led to the recommendation of 2 mm as the ideal margin width for optimal local control. However, local recurrence is also...
Source: JAMA Surgery - Category: Sports Medicine Source Type: research
Authors: Dinas KD Abstract Malignancy may unfortunately present quite early in a woman's life. In the case of breast cancer, rescue of the breast cancer patient's life is the top priority, but after completion of the effective treatment , the question about the ability to accomplish a pregnancy arises. The treatment strategies in breast cancer patients include surgical interventions, chemotherapy , radiotherapy, hormonal therapy and other special types of mainly targeted biologic therapies. Under normal circumstances, surgery for breast cancer does not involve any intervention in the ovaries or the uterus. Thus, ev...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Authors: Linhares S, Alrammah T, Alghamdi HA, Möller MG Abstract Inflammatory breast cancer (IBC) represents only 1% to 5% of all breast malignancies and is an extremely aggressive subtype. At time of diagnosis, up to 85% of patients will present with regional nodal metastases and up to 30 % will have metastasis to distant organs. There is limited medical literature describing treatment guidelines for IBC during gestation. The best diagnostic tools are core needle and full-thickness skin punch biopsies to assess presence of dermal lymphatic invasion. Breast Ultrasound is preferred to mammogram, but mammography...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Conclusion: Our prodrug-based co-delivery system may provide an effective and simple strategy to re-sensitize TNBCs to TAM-based hormone therapy.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
AbstractA prospective study on the level of concordance between core needle biopsy specimen (CNB) and surgical specimen (SS) assesses the oestrogen receptor (ER), progesterone receptor (PR) and Her2/Neu receptor status in Carcinoma breast and its implications on treatment decisions. Ninety consecutive treatment naive operable breast cancer patients treated between September 2015 and April 2017 were included in our prospective study. All patients underwent core needle biopsy prior to definitive surgery. Immunohistochemistry (IHC) studies for ER, PR, and Her2/Neu receptor assay were done in both the CNB specimen and SS. The ...
Source: Indian Journal of Surgical Oncology - Category: Cancer & Oncology Source Type: research
We report the case of a 39-year-old woman with primary breast cancer and associated synchronous bone metastases, who experienced a disease response of 12 years with hormonal therapy as maintenance after first line chemotherapy, with a good toxicity profile. Diagnosis: The patient was diagnosed with estrogen receptor + human epidermal growth factor receptor 2 (HER2)− metastatic breast cancer with synchronous bone metastases. Interventions: This patient was treated with chemotherapy for 6 cycles as a first-line therapy following by endocrine treatment given as a maintenance therapy. Outcomes: Our patient exper...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
This article summarizes the current knowledge (published studies accessed through PUBMED) on drugs used in chemotherapy, hormone therapy, anti-HER2 drugs, CDK4/6 inhibitors, PARP inhibitors, and immune therapy in breast cancer patients undergoing dialysis. We discuss the data, the optimal choice of the chemotherapeutic protocol, and the administration of drugs in a specific time relation to the haemodialysis session to ensure the most effective and safe treatment to breast cancer patients. PMID: 32508921 [PubMed]
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
Authors: Gomes I, de Almeida BP, Dâmaso S, Mansinho A, Correia I, Henriques S, Cruz-Duarte R, Vilhais G, Félix P, Alves P, Corredeira P, Barbosa-Morais NL, Costa L, Casimiro S Abstract The role of RANKL-RANK pathway in progesterone-driven mammary carcinogenesis and triple negative breast cancer tumorigenesis has been well characterized. However, and despite evidences of the existence of RANK-positive hormone receptor (HR)-positive breast tumors, the implication of RANK expression in HR-positive breast cancers has not been addressed before. Here, we report that RANK pathway affects the expression of cel...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Hormonal Therapy | Hormones | Study